phrykt

Regeneron Pharmaceuticals (REGN) cash: $3.1B

Regeneron Pharmaceuticals held $3.1B in cash and cash equivalents on Dec 31, 2025, up 25.3% from $2.5B a year earlier.

From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page

Regeneron Pharmaceuticals cash by year

$2.9B2021$3.1B2022$2.7B2023$2.5B2024$3.1B2025

#198 of 4,171 US companies by cash · See the full ranking

Year endedCashChange
Dec 31, 2025$3.1B+25%
Dec 31, 2024$2.5B-9%
Dec 31, 2023$2.7B-12%
Dec 31, 2022$3.1B+8%
Dec 31, 2021$2.9B–

Cash of similar companies

Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest cash. Each name opens the same page for that company.

CompanyCash, latest yearYear ended
AbbVie$5.2BDec 31, 2025
Vertex Pharmaceuticals Inc / Ma$5.1BDec 31, 2025
BeOne Medicines$4.5BDec 31, 2025
TEVA Pharmaceutical Industries$3.6BDec 31, 2025
Regeneron Pharmaceuticals$3.1BDec 31, 2025
Zoetis$2.5BDec 31, 2025
Alnylam Pharmaceuticals$1.7BDec 31, 2025

Questions and answers

What is Regeneron Pharmaceuticals's cash?

Regeneron Pharmaceuticals held $3.1B in cash and cash equivalents on Dec 31, 2025, up 25.3% from $2.5B a year earlier.

Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology